Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well nintedanib works in treating
patients with endometrial cancer that has come back. Nintedanib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the
tumor.